Drug Details

General Information of the Drug (ID: DR5145)
Name
Prednisolone
Synonyms
prednisolone; 50-24-8; Metacortandralone; Hydroretrocortine; Predonine; Delta-Cortef; Deltacortril; Meticortelone; Deltahydrocortisone; Prenolone; Hydroretrocortin; PRDL; Deltacortenol; Hydrodeltalone; Hydrodeltisone; Codelcortone; Cortalone; Cotogesic; Decaprednil; Delcortol; Deltisilone; Dicortol; Donisolone; Dydeltrone; Erbacort; Erbasona; Estilsona; Fernisolone; Hydeltra; Hydeltrone; Lentosone; Paracortol; Paracotol; Precortancyl; Precortilon; Precortisyl; Prednelan; Prednicen; Predniliderm; Predonin; Rolisone; Scherisolon; Sterolone; Cordrol; Prednis; Prelone; Steran; Ulacort; Fernisolone P; Hostacortin H; Ultracorten H; Ultracortene-H; Delta-stab; Predne-Dome; Decortin H; CO-Hydeltra; Eazolin D; Meti-Derm; Di-adreson F; Delta F; Derpo PD; 1-Dehydrohydrocortisone; Solone; delta(1)-Hydrocortisone; delta(1)-Dehydrocortisol; Delta-Ef-Cortelan; Dexa-Cortidelt hostacortin H; 1,2-Dehydrohydrocortisone; Prednisolona; Prednisolonum; Prednisolonum [INN-Latin]; Prednisolona [INN-Spanish]; 1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione; (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione; Ultracortene-hydrogen; Delta(1)-dehydrohydrocortisone; 1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol; UNII-9PHQ9Y1OLM; 3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene; 11beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione; K 1557; .DELTA.1-Cortisol; MFCD00003649; .DELTA.1-Hydrocortisone; 9PHQ9Y1OLM; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; .DELTA.1-Dehydrocortisol; CHEMBL131; CHEBI:8378; .DELTA.1-Dehydrohydrocortisone; 50-24-8 (free); Predniretard; Poly-Pred; .delta.-Cortef; 1-Dehydrocortisol; Neo-Delta-Cortef; Fernisolone-P; .delta.-Stab; NSC-9120; NSC-9900; Prednisolone, 99%; component of Ataraxoid; 11beta,17alpha,21-Trihydroxypregna-1,4-diene-3,20-dione; Cotolone; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11b)-; DSSTox_CID_1184; component of K-Predne-Dome; DSSTox_RID_75996; DSSTox_GSID_21184; (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; delta(1)-Cortisol; Deltasolone; Klismacort; Panafcortelone; delta(sup 1)-Cortisol; Bubbli-Pred; delta(sup 1)-Hydrocortisone; delta(sup 1)-Dehydrocortisol; SMR000718761; CCRIS 980; Prednisolone [INN:BAN:JAN]; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11.beta.)-; HSDB 3385; delta(sup 1)-Dehydrohydrocortisone; MLS002638110; NSC 9120; Pregna-1,20-dione, 11.beta.,17,21-trihydroxy-; EINECS 200-021-7; Predisolone Sodium Phosphate; BRN 1354103; prednisolon; Preflam; Pregna-1,20-dione, 11,17,21-trihydroxy-, (11.beta.)-; CAS-50-24-8; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-; NCGC00094764-01; delta-hydrocortisone; Prestwick_404; delta-dehydrocortisol; DELTA.1-Cortisol; Delta-Cortef (TN); 11-beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione; T-Pred (Salt/Mix); 1,4-Pregnadien-11-beta,17-alpha,21-triol-3,20-dione; 1,4-Pregnadiene-11-beta,17-alpha,21-triol-3,20-dione; 1,4-Pregnadiene-3,20-dione-11-beta,17-alpha,21-triol; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-; Prednisolone, >=99%; Prestwick0_000274; Prestwick1_000274; Prestwick2_000274; Prestwick3_000274; delta-dehydrohydrocortisone; EC 200-021-7; SCHEMBL3233; K-Predne-Dome (Salt/Mix); .DELTA.(sup 1)-Cortisol; BSPBio_000148; 4-08-00-03467 (Beilstein Handbook Reference); MLS001304083; MLS002154250; MLS002207037; MLS002548883; SPBio_002367; BPBio1_000164; GTPL2866; DTXSID9021184; .DELTA.(sup 1)-Hydrocortisone; BDBM19190; Prednisolone (JP17/USP/INN); NSC9120; NSC9900; .DELTA.(sup 1)-Dehydrocortisol; HMS1568H10; HMS2090J05; HMS2095H10; HMS2230P10; HMS3259E09; HMS3712H10; BCP09053; ZINC3833821; Tox21_111327; Tox21_201673; Tox21_302987; CP0099; LMST02030179; s1737; .DELTA.(sup 1)-Dehydrohydrocortisone; AKOS015894935; Tox21_111327_1; AC-1773; CCG-220274; DB00860; NC00473; NCGC00179649-01; NCGC00179649-02; NCGC00179649-03; NCGC00179649-04; NCGC00179649-06; NCGC00256577-01; NCGC00259222-01; AS-13665; HY-17463; P0637; EN300-53017; 5948-EP0930075A1; 5948-EP2272832A1; 5948-EP2277565A2; 5948-EP2277566A2; 5948-EP2277567A1; 5948-EP2277568A2; 5948-EP2277569A2; 5948-EP2277570A2; 5948-EP2277861A1; 5948-EP2277865A1; 5948-EP2281815A1; 5948-EP2292280A1; 5948-EP2295426A1; 5948-EP2295427A1; 5948-EP2298778A1; 5948-EP2301933A1; 5948-EP2305219A1; 5948-EP2305248A1; 5948-EP2305663A1; 5948-EP2308562A2; 5948-EP2308880A1; 5948-EP2311827A1; 5948-EP2314585A1; 5948-EP2314590A1; 5948-EP2316832A1; 5948-EP2316833A1; 5948-EP2371811A2; C07369; D00472; J10078; Prednisolone, VETRANAL(TM), analytical standard; 003P649; SR-01000837502; Q-201616; SR-01000837502-2; 11b,17,21-Trihydroxypregna-1,4-diene-3,20-dione; BRD-K98039984-001-03-0; BRD-K98039984-001-06-3; Q11426176; 11beta,17,21-trihydroxy-1,4-pregnadiene-3,20-dione; delta-1-Cortisol; Prednicarbate EP Imp A; Supercortisol; Prednisolone, British Pharmacopoeia (BP) Assay Standard; Z1245633279; 11-.beta.,17,21-Trihydroxypregna-1,4-diene-3,20-dione; 11beta,17alpha,21-Trihydroxy-1,4-pregnadiene-3,20-dione; (11alpha)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione; 1,4-Pregnadien-11-.beta.,17-.alpha.,21-triol-3,20-dione; 1,4-Pregnadiene-11-.beta.,17-.alpha.,21-triol-3,20-dione; 1,4-Pregnadiene-3,20-dione-11-.beta.,17-.alpha.,21-triol; Prednisolone, European Pharmacopoeia (EP) Reference Standard; Pregna-1,4-diene-3,20-dione, 11.beta.,17,21-trihydroxy-; 11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, (11.beta.)-; 11-.beta.,17-.alpha.,21-Trihydroxy-1,4-pregnadiene-3,20-dione; 11-.beta.,17-.alpha.,21-Trihydroxypregna-1,4-diene-3,20-dione; 11.beta.,17.alpha.,21-Trihydroxypregna-1,4-diene-3,20-dione; Prednisolone, United States Pharmacopeia (USP) Reference Standard; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8CI); Prednisolone for peak identification, European Pharmacopoeia (EP) Reference Standard; Prednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard; Prednisolone, Pharmaceutical Secondary Standard; Certified Reference Material; (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-3,6-dien-5-one; Prednisolone solution, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material; TUA
    Click to Show/Hide
Molecular Type
Small molecule
Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C21H28O5
PubChem CID
5755
Canonical SMILES
CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
InChI
1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
InChIKey
OIGNJSKKLXVSLS-VWUMJDOOSA-N
CAS Number
CAS 50-24-8
ChEBI ID
CHEBI:8378
TTD Drug ID
D0D1SG
DrugBank ID
DB00860
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Calcitonin      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression ODF  Molecule Info 
Pathway MAP
                    In-vitro Model U2OS CVCL_0042 Osteosarcoma Homo sapiens
SaOS-2 CVCL_0548 Osteosarcoma Homo sapiens
T-47D CVCL_0553 Invasive breast carcinoma Homo sapiens
                    In-vivo Model CIA. Female Lewis rats (150 +/- 20 g body weight) were used in this study.
                    Experimental
                    Result(s)		 Calcitonin and Prednisolone display antagonistic actions on bone and have synergistic effects in experimental Arthritis.
          Mycophenolate mofetil      Penicillium stoloniferum     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 Triple combination immunosuppressive therapy maintained with additional mycophenolate mofetil successfully controlled recurrent myocarditis, enabled a reduction in the prednisolone dose, and achieved the functional recovery of the left ventricle.
Target and Pathway
Target(s) Glucocorticoid receptor (NR3C1)  Molecule Info  [4]
KEGG Pathway Neuroactive ligand-receptor interaction Click to Show/Hide
NetPath Pathway IL2 Signaling Pathway Click to Show/Hide
2 TCR Signaling Pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling Click to Show/Hide
2 Signaling events mediated by HDAC Class II
3 FOXA2 and FOXA3 transcription factor networks
4 Glucocorticoid receptor regulatory network
5 Regulation of Androgen receptor activity
6 AP-1 transcription factor network
Reactome BMAL1:CLOCK,NPAS2 activates circadian gene expression Click to Show/Hide
WikiPathways Serotonin Receptor 4/6/7 and NR3C Signaling Click to Show/Hide
2 SIDS Susceptibility Pathways
3 Nuclear Receptors Meta-Pathway
4 Endoderm Differentiation
5 Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
6 Adipogenesis
7 Circadian Clock
8 Nuclear Receptors
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Reference 2 Calcitonin and prednisolone display antagonistic actions on bone and have synergistic effects in experimental arthritis. Am J Pathol. 2007 Mar;170(3):1018-27.
Reference 3 Successful Triple Combination Immunosuppressive Therapy with Prednisolone, Cyclosporine, and Mycophenolate Mofetil to Treat Recurrent Giant Cell Myocarditis. Intern Med. 2019 Jul 15;58(14):2035-2039.
Reference 4 Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link